$0.89
4.48%
Downside
Day's Volatility :4.48%
Upside
0.0%
15.73%
Downside
52 Weeks Volatility :76.92%
Upside
72.62%
Period | Moolec Science Sa | Index (Russel 2000) |
---|---|---|
3 Months | -17.05% | 0.0% |
6 Months | -26.64% | 0.0% |
1 Year | -69.71% | 0.0% |
3 Years | -90.25% | -20.6% |
Market Capitalization | 33.7M |
Book Value | $0.18 |
Earnings Per Share (EPS) | -0.16 |
Wall Street Target Price | 6.0 |
Profit Margin | -150.28% |
Operating Margin TTM | -96.78% |
Return On Assets TTM | -27.72% |
Return On Equity TTM | -82.56% |
Revenue TTM | 5.0M |
Revenue Per Share TTM | 0.13 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -9.4M |
Diluted Eps TTM | -0.16 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.19 |
EPS Estimate Next Year | -0.24 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 574.16%
Sell
Neutral
Buy
Moolec Science Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Moolec Science Sa | -1.38% | -26.64% | -69.71% | -90.25% | -90.25% |
Regeneron Pharmaceuticals, Inc. | -11.82% | 7.63% | 22.08% | 84.17% | 257.49% |
Novo Nordisk A/s | -12.08% | -8.57% | 27.88% | 136.23% | 343.21% |
Alnylam Pharmaceuticals, Inc. | 7.18% | 75.52% | 50.82% | 35.89% | 250.13% |
Vertex Pharmaceuticals Incorporated | -3.21% | 11.53% | 27.71% | 156.23% | 163.62% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Moolec Science Sa | NA | NA | NA | -0.19 | -0.83 | -0.28 | NA | 0.18 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Moolec Science Sa | Buy | $33.7M | -90.25% | NA | -150.28% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Insights on Moolec Science Sa
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.8% return, outperforming this stock by 120.5%
Organization | Moolec Science Sa |
Employees | 45 |
CEO | Mr. Gaston Paladini M.B.A. |
Industry | Miscellaneous |
Generation Income Properties Inc
$0.89
+0.0%
Touchstone Climate Transition Etf
$0.89
+0.0%
Atlas Lithium Corp
$0.89
+0.0%
Flexshares Quality Dividend
$0.89
+0.0%
Blackrock New York Muni Inc
$0.89
+0.0%
Timothy Plan International Etf
$0.89
+0.0%
Alger 35 Etf
$0.89
+0.0%
Aadi Bioscience Inc
$0.89
+0.0%
Goldman Sachs Access Inflati
$0.89
+0.0%